Lisata Therapeutics Stock Investor Sentiment

LSTA Stock  USD 2.82  0.02  0.70%   
About 61% of Lisata Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Lisata Therapeutics suggests that many traders are alarmed. The current market sentiment, together with Lisata Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Lisata Therapeutics stock news signals to limit their universe of possible portfolio assets.
  

Lisata Therapeutics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Lisata Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
six days ago at finance.yahoo.com         
The Dr. James Morales Grant for Medicine and Biosciences Invites Undergraduate Scholars to Apply
Yahoo News
six days ago at gurufocus.com         
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635
Gurufocus Stories at Macroaxis
over a week ago at businesswire.com         
Taconic Biosciences Announces New U.S. West Coast Production Location
businesswire News
over a week ago at simplywall.st         
Gufic Biosciences Second Quarter 2025 Earnings EPS 2.17
Simply Wall St News at Macroaxis
over a week ago at gurufocus.com         
Forte Biosciences, Inc. Announces Oversubscribed 53 Million Private Placement From Leading ...
Gurufocus Stories at Macroaxis
over a week ago at gurufocus.com         
Artelo Biosciences Stock Surges Amid Strong Buy Ratings
Gurufocus Stories at Macroaxis
over a week ago at finance.yahoo.com         
Alamar Biosciences Announces Collaboration with The Michael J. Fox Foundation to Advance Parkinsons ...
Yahoo News
over a week ago at globenewswire.com         
Cytek Biosciences Named Overall BioTech Company of the Year in 2024 BioTech Breakthrough Awards Prog...
Macroaxis News: globenewswire.com
over a week ago at prnewswire.com         
Concerto Biosciences Announces First Participant Dosed with Live Biotherapeutic ENS-002 in Phase 1 T...
prnewswire News
over a week ago at prnewswire.com         
Alamar Biosciences Announces Collaboration with The Michael J. Fox Foundation to Advance Parkinsons ...
prnewswire News
over a week ago at kalkinemedia.com         
Alamar Biosciences Announces Collaboration with The Michael J. Fox Foundation to Advance Parkinsons ...
news
over a week ago at finance.yahoo.com         
Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD - The...
Yahoo News
over a week ago at finance.yahoo.com         
Arcadia Biosciences Q3 Earnings Miss Estimates, Sales Increase YY
Yahoo News
over a week ago at finance.yahoo.com         
Artelo Biosciences to Present Key Data on Three Development Programs at the 7th Cannabinoid Drug Dev...
Yahoo News
over a week ago at simplywall.st         
institutional investors of Inhibrx Biosciences, Inc. must be disappointed after last weeks 15 percen...
Simply Wall St News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Lisata Therapeutics that are available to investors today. That information is available publicly through Lisata media outlets and privately through word of mouth or via Lisata internal channels. However, regardless of the origin, that massive amount of Lisata data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Lisata Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Lisata Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Lisata Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Lisata Therapeutics alpha.

Lisata Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Castle Biosciences Inc Trading 3.24 percent Higher on Oct 29
10/29/2024
2
Cytek Biosciences, Inc. Q3 Earnings and Revenues Beat Estimates
11/05/2024
3
Artelo Biosciences Stock Dips Amidst Financial Report
11/13/2024
4
Artelo Biosciences to Present Key Data on Three Development Programs at the 7th Cannabinoid Drug Development Summit
11/18/2024
5
Alamar Biosciences Announces Collaboration with The Michael J. Fox Foundation to Advance Parkinsons Research Through Development of Next Generation Biomarker As...
11/19/2024
6
Forte Biosciences, Inc. Announces Oversubscribed 53 Million Private Placement From Leading ...
11/20/2024
7
The Dr. James Morales Grant for Medicine and Biosciences Invites Undergraduate Scholars to Apply
11/21/2024
8
Anixa Biosciences board approves purchase of Bitcoin as treasury reserve asset
11/22/2024
9
Aptose Biosciences Inc. Announces Closing of 8 Million Public Offering
11/25/2024

Complementary Tools for Lisata Stock analysis

When running Lisata Therapeutics' price analysis, check to measure Lisata Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lisata Therapeutics is operating at the current time. Most of Lisata Therapeutics' value examination focuses on studying past and present price action to predict the probability of Lisata Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lisata Therapeutics' price. Additionally, you may evaluate how the addition of Lisata Therapeutics to your portfolios can decrease your overall portfolio volatility.
Transaction History
View history of all your transactions and understand their impact on performance
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges